TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Completed · Phase 1
Conditions studied: Solid Tumor, Lymphoma
In brief
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies.
Key facts
- Study ID
- NCT03884556
- Run by
- Trishula Therapeutics, Inc.
- People needed
- 56
- Starts
- 2019-04-10
- Expected to finish
- 2023-09-29
- Last updated by the study team
- 2025-07-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UC Irvine Cancer Center — Orange, California, United States
- UC Davis Comprehensive Cancer Center — Sacramento, California, United States
- University of California, San Francisco — San Francisco, California, United States
- Sylvester Comprehensive Cancer Center — Miami, Florida, United States
- Norton Cancer Institute — Louisville, Kentucky, United States
- Nebraska Cancer Center Oncology Hematology West P.C. — Omaha, Nebraska, United States
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- Columbia University Irving Medical Center — New York, New York, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Montefiore Medical Center — The Bronx, New York, United States
- University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
- West Cancer Center and Research Institute — Germantown, Tennessee, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- NEXT Oncology — San Antonio, Texas, United States
- Huntsman Cancer Intitute — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.